These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32411232)

  • 1. GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial.
    Jia R; Mi Y; Yuan X; Kong D; Li W; Li R; Wang B; Zhu Y; Kong J; Ma Z; Li N; Mi Q; Gao S
    J Oncol; 2020; 2020():1607860. PubMed ID: 32411232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation.
    Jia R; Yang L; Yuan X; Kong J; Liu Y; Yin W; Gao S; Zhang Y
    J Oncol; 2019; 2019():1621054. PubMed ID: 31031809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
    Sun LL; Holowatyj A; Xu XE; Wu JY; Wu ZY; Shen JH; Wang SH; Li EM; Yang ZQ; Xu LY
    Am J Cancer Res; 2013; 3(5):509-17. PubMed ID: 24224128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
    Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
    World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
    J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiation treatment followed by surgery for esophageal cancer: there is much more than the mandard tumor regression score.
    Depypere L; Moons J; Lerut T; De Hertogh G; Sagaert X; Coosemans W; Van Veer H; Renders A; Nafteux P
    Acta Chir Belg; 2016 Jun; 116(3):149-155. PubMed ID: 27472306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of GRASP on DCE-MRI for assessing response to neoadjuvant chemotherapy in patients with esophageal cancer.
    Lu Y; Ma L; Qin J; Wang Z; Guo J; Zhao Y; Zhang H; Yan X; Liu H; Li H; Kamel IR; Qu J
    BMC Cancer; 2019 Oct; 19(1):999. PubMed ID: 31651280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
    Uimonen K; Merikallio H; Pääkkö P; Harju T; Mannermaa A; Palvimo J; Kosma VM; Soini Y
    Histol Histopathol; 2014 Jun; 29(6):797-804. PubMed ID: 24371038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.
    Vecchio FM; Valentini V; Minsky BD; Padula GD; Venkatraman ES; Balducci M; Miccichè F; Ricci R; Morganti AG; Gambacorta MA; Maurizi F; Coco C
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):752-60. PubMed ID: 15936556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
    Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
    Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can tumor regression grade influence survival outcome in ypT3 rectal cancer?
    Shen L; Wang L; Li G; Zhang H; Liang L; Fan M; Wu Y; Deng W; Sheng W; Zhu J; Zhang Z
    Clin Transl Oncol; 2016 Jul; 18(7):693-9. PubMed ID: 26527031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
    Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
    Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
    Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
    Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
    Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
    Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.